期刊文献+

Controlled Release of Doxorubicin from Electrospun MWCNTs/PLGA Hybrid Nanofibers 被引量:3

Controlled Release of Doxorubicin from Electrospun MWCNTs/PLGA Hybrid Nanofibers
原文传递
导出
摘要 In this study, multiwalled carbon nanotubes (MWCNTs) were used to encapsulate a model anticancer drug, doxorubicin (Dox). Then, the drug-loaded MWCNTs (Dox/MWCNTs) with an optimized drug encapsulation percentage were mixed with poly(lactide-co-glycolide) (PLGA) polymer solution for subsequent electrospinning to form drug-loaded composite nanofibrous mats. The structure, morphology, and mechanical properties of the formed electrospun Dox/PLGA, MWCNTs/PLGA, and Dox/MWCNTs/PLGA composite nanofibrous mats were characterized using scanning electron microscopy (SEM), Fourier transform infrared spectroscopy, and tensile testing. In vitro viability assay and SEM morphology observation of mouse fibroblast cells cultured onto the MWCNTs/PLGA fibrous scaffolds demonstrate that the developed MWCNTs/PLGA composite nanofibers are cytocompatible. The incorporation of Dox-loaded MWCNTs within the PLGA nanofibers is able to improve the mechanical durability and maintain the three-dimensional structure of the nanofibrous mats. More importantly, our results indicate that this double-container drug delivery system (both PLGA polymer and MWCNTs are drug carriers) is beneficial to avoid the burst release of the drug and able to release the antitumor drug Dox in a sustained manner for 42 days. The developed composite electrospun nanofibrous drug delivery system may be used as therapeutic scaffold materials for post-operative local chemotherapy. In this study, multiwalled carbon nanotubes (MWCNTs) were used to encapsulate a model anticancer drug, doxorubicin (Dox). Then, the drug-loaded MWCNTs (Dox/MWCNTs) with an optimized drug encapsulation percentage were mixed with poly(lactide-co-glycolide) (PLGA) polymer solution for subsequent electrospinning to form drug-loaded composite nanofibrous mats. The structure, morphology, and mechanical properties of the formed electrospun Dox/PLGA, MWCNTs/PLGA, and Dox/MWCNTs/PLGA composite nanofibrous mats were characterized using scanning electron microscopy (SEM), Fourier transform infrared spectroscopy, and tensile testing. In vitro viability assay and SEM morphology observation of mouse fibroblast cells cultured onto the MWCNTs/PLGA fibrous scaffolds demonstrate that the developed MWCNTs/PLGA composite nanofibers are cytocompatible. The incorporation of Dox-loaded MWCNTs within the PLGA nanofibers is able to improve the mechanical durability and maintain the three-dimensional structure of the nanofibrous mats. More importantly, our results indicate that this double-container drug delivery system (both PLGA polymer and MWCNTs are drug carriers) is beneficial to avoid the burst release of the drug and able to release the antitumor drug Dox in a sustained manner for 42 days. The developed composite electrospun nanofibrous drug delivery system may be used as therapeutic scaffold materials for post-operative local chemotherapy.
出处 《Chinese Journal of Polymer Science》 SCIE CAS CSCD 2016年第9期1047-1047,1048-1059,共13页 高分子科学(英文版)
基金 financially supported by the“111 Project”(No.B07024) the Fundamental Research Funds for the Central Universities(for R.Guo,M.Shen and X.Shi) the Program for Professor of Special Appointment(Eastern Scholar)at Shanghai Institutions of Higher Learning the Program for Innovative Research Team(in Science and Technology)in University of Henan Province(No.13IRTSTHN024)
关键词 Electrospun nanofibers Carbon nanotubes DOXORUBICIN Controlled release. Electrospun nanofibers Carbon nanotubes Doxorubicin Controlled release.
  • 相关文献

参考文献44

  • 1Liu, W., Wen, S., Shen, M. and Shi, X., New J. Chem., 2014, 38:3917.
  • 2Wang, S., Wu, Y., Guo, R., Huang, Y., Wen, S., Shen, M., Wang, J. and Shi, X., Langmuir, 2013, 29(16): 5030.
  • 3Peer, D., Karp, J.M., Hong, S., FaroKhzad, O.C., Margalit, R. and Langer, R., Nat. Nanotechnol., 2007, 2(12): 751.
  • 4Goldberg, M., Langer, R. and Jia, X.Q., J. Biomater. Sci. Polym. Ed., 2007, 18(3): 241.
  • 5Wen, S., Liu, H., Cai, H., Shen, M. and Shi, X., Adv. Healthcare Mater., 2013, 2:1267.
  • 6Fu, F., Wu, Y., Zhu, J., Wen, S., Shen, M. and Shi, X., ACS Appl. Mater. Interfaces, 2014, 6:16416.
  • 7Wang, Y., Cao, X., Guo, R., Shen, M., Zhang, M., Zhu, M. and Shi, X., Polym. Chem., 2011, 2(8): 1754.
  • 8Maciel, D., Figueira, P., Xiao, S., Hu, D., Shi, X., Rodrigues, J., Tomars, H. and Li, Y., Biomacromolecules, 2013, 14(9): 3140.
  • 9Abbasi, A., Nasef, M.M., Takeshi, M. and Faridi-Majidi, R., Chinese J. Polym. Sci., 2014, 32(6): 793.
  • 10Sill, T.J. and von Recum, H.A., Biomaterials, 2008, 29(13): 1989.

同被引文献3

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部